`
`Page 6
`
`Art Unit: 1643
`
`11.
`
`The specification is objected to because the use of
`
`improperly demarcated
`
`trademarks has been noted in this application. Although the use of trademarks is
`
`permissible in patent applications,
`
`the proprietary nature of
`
`the marks should be
`
`respected and every effort made to prevent
`
`their use in any manner that might
`
`adversely affect their validity as trademarks. See MPEP § 608.01 (v).
`
`An example of such an improperly demarcated trademark appearing in the
`
`specification is BiacoreT'V'; see, e.g., paragraph [0282] of the published application2.
`
`Appropriate correction is
`
`required.
`
`Each letter of a trademark should be
`
`capitalized or otherwise the trademark should be demarcated with the appropriate
`
`symbol
`
`indicating its proprietary nature (e.g., TM, ®), and accompanied by generic
`
`terminology. Applicants may identify trademarks using the “Trademark” search engine
`
`under
`
`“USPTO
`
`Search
`
`Collections”
`
`on
`
`the
`
`Internet
`
`at
`
`http://www.uspto.gov/web/menu/search.html.
`
`12.
`
`Claim 3 is objected to because of the redundant recitation of “wherein the
`
`antibody reduces ligand-induced growth of an ErbB-2 and ErbB-3 positive cell”‘°’.
`
`Claim Objections
`
`13.
`
`Claim 3 is objected to because the claim recites, “wherein the cell has at least
`
`100.000 ErbB-2 cell-surface receptors per cell”. As the claim refers to only one cell
`
`it
`
`makes no sense to refer to the number of receptors per cell.
`
`It is suggested that this issue might best be remedied by amending the claim to
`
`recite, for example, “wherein the cell is a cell having at least 100,000 copies of ErbB-2
`
`on its surface”.
`
`2 U.S. Patent Application Publication No. 2017/0037145-A1.
`
`3 Claim 3 depends from claim 2, which recites this same limitation.
`
`